Vilanterol trifenatate/fluticasone furoate, lomitapide mesylate, and mipomersen sodium.
作者信息
Hussar Daniel A, Ahmad Afsheen
出版信息
J Am Pharm Assoc (2003). 2013 Nov-Dec;53(6):662-70. doi: 10.1331/JAPhA.2013.13538.
PMID:24185435
Abstract
摘要
相似文献
1
Vilanterol trifenatate/fluticasone furoate, lomitapide mesylate, and mipomersen sodium.
J Am Pharm Assoc (2003). 2013 Nov-Dec;53(6):662-70. doi: 10.1331/JAPhA.2013.13538.
2
Fluticasone-vilanterol combination approved for COPD.
Am J Health Syst Pharm. 2013 Jun 15;70(12):1008. doi: 10.2146/news130042.
3
Pharmacokinetics and Systemic Activity of a New Patent of an Inhaled Corticosteroid/Long-Acting β2-Agonist Combination for Use in Asthma Therapy: Fluticasone Furoate/Vilanterol Trifenatate.
Recent Pat Inflamm Allergy Drug Discov. 2015;9(2):144-50. doi: 10.2174/1872213x10666151119144907.
4
Relvar Ellipta for asthma.
Drug Ther Bull. 2014 Aug;52(8):93-6. doi: 10.1136/dtb.2014.8.0273.
5
▼Relvar Ellipta for COPD.
Drug Ther Bull. 2014 Jun;52(6):66-9. doi: 10.1136/dtb.2014.6.0258. Epub 2014 Jun 5.
6
Breo Ellipta: An Inhaled Fluticasone/ Vilanterol Combination for COPD.
Med Lett Drugs Ther. 2013 Sep 2;55(1424):69-71, 45-8.
7
Combination of fluticasone furoate and vilanterol for the treatment of chronic obstructive pulmonary disease.
Ann Pharmacother. 2014 Feb;48(2):250-7. doi: 10.1177/1060028013512615. Epub 2013 Nov 19.
8
Short- and long-term effects of fluticasone furoate/vilanterol in exercising asthmatic adolescents: A randomized and open label trial.
Basic Clin Pharmacol Toxicol. 2021 Nov;129(5):369-375. doi: 10.1111/bcpt.13640. Epub 2021 Aug 25.
9
Cost-consequence analysis of fluticasone furoate/vilanterol for asthma management in Spain: an analysis based on the Salford Lung Study in asthma.
Eur J Health Econ. 2020 Feb;21(1):7-17. doi: 10.1007/s10198-019-01101-x. Epub 2019 Sep 23.
10
Phamacology of fluticasone furoate and vilanterol trifenatate combination therapy for asthma.
Expert Rev Respir Med. 2016 Oct;10(10):1069-78. doi: 10.1080/17476348.2016.1227245. Epub 2016 Sep 7.
引用本文的文献
1
Profile of fluticasone furoate/vilanterol dry powder inhaler combination therapy as a potential treatment for COPD.
Int J Chron Obstruct Pulmon Dis. 2014 Feb 24;9:249-56. doi: 10.2147/COPD.S32604. eCollection 2014.
Zotero 插件